Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial
Background Dexamethasone 6 mg daily for 10 days is the recommended treatment for patients with severe or critical coronavirus disease 2019 (COVID-19). The evidence on the benefit of high-dose dexamethasone is limited. The goal of this study was to assess the effects of 6 mg daily vs. 20 mg daily of...
Saved in:
Published in | PloS one Vol. 17; no. 10 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Public Library of Science (PLoS)
01.01.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background Dexamethasone 6 mg daily for 10 days is the recommended treatment for patients with severe or critical coronavirus disease 2019 (COVID-19). The evidence on the benefit of high-dose dexamethasone is limited. The goal of this study was to assess the effects of 6 mg daily vs. 20 mg daily of dexamethasone in hospitalized patients with COVID-19 pneumonia. Methods We conducted a single-center, randomized, clinical trial involving hospitalized patients with COVID-19 pneumonia. Participants were randomized 1:1 to dexamethasone 6 mg daily or dexamethasone 20 mg daily, and were stratified by the WHO-Ordinal Scale for Clinical Improvement (OSCI). The primary outcome was clinical improvement equal to or greater than 2 points by OSCI on day 28. Secondary outcomes were 28-day mortality, intensive care unit-free days, and ventilator-free days on day 28. Results Of the 107 patients who enrolled and completed the follow up, 55 patients enrolled in the low-dose group and 52 patients enrolled in the high-dose group. Treatment with dexamethasone 20 mg daily compared with dexamethasone 6 mg daily did not result in better clinical improvement based on OSCI on day 28 (71.2% vs. 78.2%; odds ratio, 1.45 [0.55–3.86]; p = 0.403). For participants who required high-flow oxygen or noninvasive ventilation at randomization, the 6-mg group had better survival than the 20-mg group on day 28 (100% vs. 57.1%; p = 0.025). Although more participants in the 6-mg group received immune modulators (40% vs. 21.2%; p = 0.035), 50% of death cases in the 20-mg group who required high-flow oxygen or noninvasive ventilation at randomization received immune modulators. Conclusions Dexamethasone 20 mg daily did not result in better clinical outcome improvement, and was probably associated with higher 28-day mortality in patients on high-flow oxygen or noninvasive ventilation, compared with dexamethasone 6 mg daily. Trial registration Clinialtrials.gov number, NCT04707534, registered January 13, 2021 |
---|---|
AbstractList | Background Dexamethasone 6 mg daily for 10 days is the recommended treatment for patients with severe or critical coronavirus disease 2019 (COVID-19). The evidence on the benefit of high-dose dexamethasone is limited. The goal of this study was to assess the effects of 6 mg daily vs. 20 mg daily of dexamethasone in hospitalized patients with COVID-19 pneumonia. Methods We conducted a single-center, randomized, clinical trial involving hospitalized patients with COVID-19 pneumonia. Participants were randomized 1:1 to dexamethasone 6 mg daily or dexamethasone 20 mg daily, and were stratified by the WHO-Ordinal Scale for Clinical Improvement (OSCI). The primary outcome was clinical improvement equal to or greater than 2 points by OSCI on day 28. Secondary outcomes were 28-day mortality, intensive care unit-free days, and ventilator-free days on day 28. Results Of the 107 patients who enrolled and completed the follow up, 55 patients enrolled in the low-dose group and 52 patients enrolled in the high-dose group. Treatment with dexamethasone 20 mg daily compared with dexamethasone 6 mg daily did not result in better clinical improvement based on OSCI on day 28 (71.2% vs. 78.2%; odds ratio, 1.45 [0.55–3.86]; p = 0.403). For participants who required high-flow oxygen or noninvasive ventilation at randomization, the 6-mg group had better survival than the 20-mg group on day 28 (100% vs. 57.1%; p = 0.025). Although more participants in the 6-mg group received immune modulators (40% vs. 21.2%; p = 0.035), 50% of death cases in the 20-mg group who required high-flow oxygen or noninvasive ventilation at randomization received immune modulators. Conclusions Dexamethasone 20 mg daily did not result in better clinical outcome improvement, and was probably associated with higher 28-day mortality in patients on high-flow oxygen or noninvasive ventilation, compared with dexamethasone 6 mg daily. Trial registration Clinialtrials.gov number, NCT04707534, registered January 13, 2021 |
Author | Brent Brown Jarrod Harper Salim Daouk Huimin Wu Jad Kebbe Fawad Chaudry |
Author_xml | – sequence: 1 fullname: Huimin Wu – sequence: 2 fullname: Salim Daouk – sequence: 3 fullname: Jad Kebbe – sequence: 4 fullname: Fawad Chaudry – sequence: 5 fullname: Jarrod Harper – sequence: 6 fullname: Brent Brown |
BookMark | eNqtjcFKAzEURYMo2Kr_8H5gYGYynbbupCoWBDfiNrwmL80rmWRI0lb9ekv1E1xdOFzOmYrLEANdiEmzlG3Vt7W8FtOcd3U9k4u-n4jDazxWJmaCA6W8z-B4636BoU8cqDjMJwXYmMDFPHJBz99kYMTCFEqGIxcHq7eP9WPVLGEMtB9iYLyHB0gYTBzOd-05sEYPJTH6W3Fl0We6-9sbsX5-el-9nMq4U2PiAdOXisjqDGLaKkyFtSdlZTefkWw70rrTJDeLDTYWO2lMP2-skf_p-gHtbGmR |
ContentType | Journal Article |
DBID | DOA |
DatabaseName | Directory of Open Access Journals |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
EISSN | 1932-6203 |
ExternalDocumentID | oai_doaj_org_article_f3475e324ecc4ce3b8ba1fa43dd671fd |
GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV AEAQA AENEX AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BBORY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESTFP ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 P2P P62 PATMY PDBOC PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM |
ID | FETCH-doaj_primary_oai_doaj_org_article_f3475e324ecc4ce3b8ba1fa43dd671fd3 |
IEDL.DBID | DOA |
IngestDate | Tue Oct 22 15:13:32 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-doaj_primary_oai_doaj_org_article_f3475e324ecc4ce3b8ba1fa43dd671fd3 |
OpenAccessLink | https://doaj.org/article/f3475e324ecc4ce3b8ba1fa43dd671fd |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f3475e324ecc4ce3b8ba1fa43dd671fd |
PublicationCentury | 2000 |
PublicationDate | 2022-01-01 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | PloS one |
PublicationYear | 2022 |
Publisher | Public Library of Science (PLoS) |
Publisher_xml | – name: Public Library of Science (PLoS) |
SSID | ssj0053866 |
Score | 4.4416785 |
Snippet | Background Dexamethasone 6 mg daily for 10 days is the recommended treatment for patients with severe or critical coronavirus disease 2019 (COVID-19). The... |
SourceID | doaj |
SourceType | Open Website |
Title | Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial |
URI | https://doaj.org/article/f3475e324ecc4ce3b8ba1fa43dd671fd |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV09T8MwED2hsrAgyof4rG5ggMGiSRwnsLWlVYugIASoW2TXtuhAU5EWEL-es5NKMDHAaln26WzfO1u-9wCOKWeVYSg1kzGPGCeMZUooyVQ6Fl6kxvhysZuh6D_yq1E8-ib15f6ElfTApePObMST2BDs01x8bCKVKhlYySOtRRJY7aNvM1xepsoYTKdY_GTh93DR24D1Ks_DVjl-HVbMdBPq1Ukq8KSiez7dgrfr_J3pvDDofkgsCnQMwmWDNh_SSTxLSooNUnqJz5XMx-TTaKw4UQt0j6nYuX0aXLLgHGdTs6DNNZEX2EKCIp2_-O7LIkj0Sh3bMOh1Hzp95qzPZiXpROZooH0DOSernJP95pxoB2pTsnAXMJXWciHTREWWJ8IquhjHqmnDNNWBaOo9aP99vv3_GOQA1kJXY-DfOQ6hNn9dmCNC_rlqwGq7O7y7b_jF_gLo47q- |
link.rule.ids | 314,780,784,2102 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-dose+versus+high-dose+dexamethasone+for+hospitalized+patients+with+COVID-19+pneumonia%3A+A+randomized+clinical+trial&rft.jtitle=PloS+one&rft.au=Huimin+Wu&rft.au=Salim+Daouk&rft.au=Jad+Kebbe&rft.au=Fawad+Chaudry&rft.date=2022-01-01&rft.pub=Public+Library+of+Science+%28PLoS%29&rft.eissn=1932-6203&rft.volume=17&rft.issue=10&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_f3475e324ecc4ce3b8ba1fa43dd671fd |